Terug
Ook genoteerd als
GLAXF
OTC
Dagbereik
€ 51,80
€ 52,69
52-Weeksbereik
€ 32,38
€ 61,70
Volume
4.212.688
50D / 200D Gem.
€ 54,58
/
€ 45,66
Vorige Slotkoers
€ 51,84
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 18,7 | 0,4 |
| P/B | 6,4 | 2,9 |
| ROE % | 37,3 | 3,7 |
| Net Margin % | 17,5 | 3,8 |
| Rev Growth 5Y % | 6,7 | 10,0 |
| D/E | 1,1 | 0,2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
10 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 |
Braunstein Scott
|
sell | 29.956 | — | — |
| Mar 3, 2026 |
Dombkowski Ashley L.
|
sell | 29.956 | — | — |
| Mar 3, 2026 |
Lyons-Williams Lori
|
sell | 47.240 | — | — |
| Mar 3, 2026 |
Giordano Michael F
|
sell | 48.328 | — | — |
| Mar 3, 2026 |
Young Rodney KB
CHIEF FINANCIAL OFFICER
|
sell | 205.703 | — | — |
| Mar 3, 2026 |
Kozick Linda
|
sell | 51.762 | — | — |
| Mar 3, 2026 |
Brockstedt Dirk G.
CHIEF SCIENTIFIC OFFICER
|
sell | 164.742 | — | — |
| Mar 3, 2026 |
GRAY MARY ANN
|
sell | 59.858 | — | — |
| Mar 3, 2026 |
Wong Brian Russell
PRESIDENT AND CEO
|
sell | 827.353 | — | — |
| Dec 11, 2025 |
GSK plc
10% Owner
|
buy | 1.470.000 | € 19,00 | € 27.930.000 |
Belangrijkste Punten
Revenue grew 6,65% annually over 5 years — modest growth
Earnings grew 117,12% over the past year
ROE of 37,25% indicates high profitability
Net margin of 17,50% shows strong profitability
Generating 5,82B in free cash flow
PEG of 0,11 suggests growth is underpriced
Groei
Revenue Growth (5Y)
6,65%
Revenue (1Y)1,83%
Earnings (1Y)117,12%
FCF Growth (3Y)-3,52%
Kwaliteit
Return on Equity
37,25%
ROIC15,45%
Net Margin17,50%
Op. Margin21,95%
Veiligheid
Debt / Equity
1,08
Current Ratio0,82
Interest Coverage10,23
Waardering
P/E Ratio
18,68
P/B Ratio6,39
EV/EBITDA16,93
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,83% | Revenue Growth (3Y) | 2,64% |
| Earnings Growth (1Y) | 117,12% | Earnings Growth (3Y) | 6,51% |
| Revenue Growth (5Y) | 6,65% | Earnings Growth (5Y) | 6,26% |
| Profitability | |||
| Revenue (TTM) | 31,95B | Net Income (TTM) | 5,59B |
| ROE | 37,25% | ROA | 9,16% |
| Gross Margin | 72,54% | Operating Margin | 21,95% |
| Net Margin | 17,50% | Free Cash Flow (TTM) | 5,82B |
| ROIC | 15,45% | FCF Growth (3Y) | -3,52% |
| Safety | |||
| Debt / Equity | 1,08 | Current Ratio | 0,82 |
| Interest Coverage | 10,23 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 18,68 | P/B Ratio | 6,39 |
| P/S Ratio | 3,27 | PEG Ratio | 0,11 |
| EV/EBITDA | 16,93 | Dividend Yield | 0,03% |
| Market Cap | 104,42B | Enterprise Value | 118,72B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31,95B | 31,38B | 30,33B | 29,32B | 24,70B |
| Net Income | 5,59B | 2,58B | 4,93B | 14,96B | 4,39B |
| EPS (Diluted) | 2,72 | 1,24 | 2,40 | 2,40 | 2,70 |
| Gross Profit | 23,18B | 22,33B | 21,76B | 19,77B | 16,53B |
| Operating Income | 7,01B | 4,02B | 6,75B | 6,43B | 4,36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 61,01B | 59,46B | 75,22B | 60,15B | 107,14B |
| Total Liabilities | 45,02B | 46,38B | 58,91B | 50,05B | 78,23B |
| Shareholders' Equity | 16,35B | 13,67B | 17,01B | 10,60B | 20,39B |
| Total Debt | 17,69B | 16,99B | 22,97B | 20,99B | 32,74B |
| Cash & Equivalents | 3,39B | 3,69B | 3,74B | 3,72B | 5,79B |
| Current Assets | 17,48B | 17,00B | 23,77B | 20,77B | 25,29B |
| Current Liabilities | 21,35B | 21,70B | 26,86B | 22,81B | 32,06B |